Platelet Activation and Progression to Complications

Rev Cardiovasc Med. Spring 2006;7(2):75-81.

Abstract

Platelets localize, amplify, and sustain the coagulant response at an injury site and release procoagulant platelet-derived microparticles. Abnormalities in platelet size and function may be present in acute coronary syndromes and following percutaneous coronary intervention (PCI). Platelet functional assessment prior to PCI is a predictor for the subsequent occurrence of adverse clinical events. Trials of glycoprotein IIb-IIIa inhibitors as adjunctive pharmacotherapy for PCI show that the magnitude of platelet inhibition achieved by therapy correlates with the degree of clinical benefit observed. In general, optimal periprocedural outcomes require high levels of platelet inhibition. Combined administration of antiplatelet therapies may produce additive or synergistic inhibition of platelet-mediated thrombosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Angioplasty, Balloon, Coronary* / adverse effects
  • Blood Coagulation
  • Blood Platelets / drug effects*
  • Blood Platelets / metabolism
  • Coronary Disease / blood
  • Coronary Disease / therapy*
  • Humans
  • Platelet Activation*
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Platelet Glycoprotein GPIIb-IIIa Complex / metabolism
  • Randomized Controlled Trials as Topic
  • Syndrome
  • Thrombosis / etiology
  • Thrombosis / prevention & control*
  • Treatment Outcome

Substances

  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex